Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 5.98 | 1.05 | 19.72 | 26.96 |
Op profit growth | -1.36 | 21.68 | -2.25 | 49.52 |
EBIT growth | 3.23 | 25.54 | -9.12 | 45.94 |
Net profit growth | 110.31 | 81.33 | -33.74 | 19.36 |
Profitability ratios (%) | ||||
OPM | 21.88 | 23.51 | 19.52 | 23.91 |
EBIT margin | 18.68 | 19.18 | 15.44 | 20.34 |
Net profit margin | 29.39 | 14.81 | 8.25 | 14.91 |
RoCE | 12.65 | 13.22 | 12.07 | 16.17 |
RoNW | 7.48 | 4.56 | 3.07 | 5.65 |
RoA | 4.97 | 2.55 | 1.61 | 2.96 |
Per share ratios (₹) | ||||
EPS | 44.65 | 20.87 | 11.48 | 17.07 |
Dividend per share | 2.5 | 3.5 | 3.5 | 3.5 |
Cash EPS | 36.86 | 14.3 | 4.68 | 12.08 |
Book value per share | 166.05 | 126.9 | 101.35 | 85.41 |
Valuation ratios | ||||
P/E | 7.8 | 21.12 | 23.26 | 22.18 |
P/CEPS | 9.45 | 30.82 | 56.95 | 31.33 |
P/B | 2.09 | 3.47 | 2.63 | 4.43 |
EV/EBIDTA | 10.88 | 14.23 | 11.86 | 14.47 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 20.17 |
Tax payout | -18.77 | -7.43 | -17.2 | -24.21 |
Liquidity ratios | ||||
Debtor days | 77.32 | 86.03 | 87.95 | 84.06 |
Inventory days | 83.15 | 76.34 | 66.25 | 64.21 |
Creditor days | -69.99 | -74.42 | -65.7 | -73.35 |
Leverage ratios | ||||
Interest coverage | -22.45 | -17.39 | -6.43 | -26.58 |
Net debt / equity | 0.18 | 0.28 | 0.67 | 0.46 |
Net debt / op. profit | 0.93 | 1.09 | 2.52 | 1.43 |
Cost breakup (₹) | ||||
Material costs | -36.32 | -33.33 | -34.51 | -34.62 |
Employee costs | -15.94 | -15.93 | -16.94 | -15.57 |
Other costs | -25.84 | -27.21 | -29.01 | -25.87 |
EBITDA for Q2 increased by 27.5% year-on-year to ₹1,461.4 crore, with EBITDA margins expanding by 170 basis points to 27.9%.
Here are some of the stocks that may see significant price movement today: Reliance Industries, HCLTech, Sunteck Realty, etc.
According to a regulatory filing by Zydus Lifesciences, the USFDA approved Paliperidone extended-release tablets.
Patients with metastatic castration-sensitive prostate cancer and castration-resistant prostate cancer are recommended to be treated with enzalutamide tablets.
The purchase will be on a slump sale basis, treating it as a going concern, with a cash-free and debt-free transaction at a lump-sum consideration of ₹840 million.
Zydus will take charge of marketing, distributing, and selling these MRI contrast agents in the US market, marking its entry into the contrast agent product category.
The warning letter specifically cites Zydus’s failure to properly investigate contamination issues in drug products at its Jarod plant in Vadodara district.
Here are some of the stocks that may see significant price movement today: Adani Power & Adani Green, Hindustan Unilever, Dixon Technologies, etc.
As per USFDA, the facility did not thoroughly analyse contamination across medicine batches and continued to issue compromised items.
Usnoflast is a new NLRP3 inhibitor showing promise in the Phase II(a) trial, offering hope for ALS patients, a disease characterized by severe inflammation and rapid muscle control loss.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.